Application of angiogenesis to clinical dermatology.
Application of angiogenesis to clinical dermatology.
复制标题
DOI：
10.1016/j.yadr.2008.09.010
复制
发表时间：
2008-01-01
期刊：
影响因子：
--
通讯作者：
Arbiser, Jack L
中科院分区：
文献类型：
--
作者：
Fried, Levi E;Arbiser, Jack L
正如博士在本章中所定义的。 Fried 和 Arbiser 认为，血管生成是“正常组织和病理组织获得血液供应的过程”。越来越多的证据表明，血管生成在炎症和肿瘤过程中发挥着关键作用。了解血管生成的分子基础，包括骨髓内皮细胞前体归巢到新建立的血管生成位点，为我们提供了许多与血管形成或维持相关的潜在治疗靶点。最近批准的抗 VEGF 抗体贝伐珠单抗用于癌症治疗就是一个这样的例子，还有更多的例子似乎正在酝酿之中。本综述的资深作者 Jack Arbiser 博士一直是阐明血管生成的分子基础（例如活性氧的作用）的领导者，也是使用新药和既定药物（例如龙胆紫）在各种情况下阻断血管生成的先驱，包括与皮肤病学相关的血管瘤的治疗。
As defined in this chapter by Drs. Fried and Arbiser, angiogenesis is “the process by which normal and pathologic tissue derives a blood supply”. Increasingly, angiogenesis has been shown to play critical roles in inflammatory as well as neoplastic processes. Understanding the molecular basis of angiogenesis, including the homing of bone marrow endothelial cell precursors to newly established sites of angiogenesis, has given us many potential therapeutic targets related to formation or maintenance of blood vessels. The recent approval of an anti-VEGF antibody, bevacizumab, for cancer therapy is one such example and many more appear to be on their way. Dr. Jack Arbiser, the senior author of this review, has been a leader in elucidating the molecular basis of angiogenesis (eg, the role of reactive oxygen species) as well as pioneer in using new and established drugs (eg, gentian violet) to block angiogenesis in a variety of settings, including the treatment of hemangiomas, that have relevance in dermatology.